Which Regulatory Approvals Are Vital in M&A Transactions?

Financial and legal document review must begin with a structured assessment of revenue quality, customer concentration, and contingent liabilities rather than a passive receipt of data. You should focus on identifying contracts that require third-party consent for assignment, material adverse change clauses that could trigger termination rights, and any pending litigation or regulatory investigations that could affect valuation. In practice, many transactions stall because the seller has not disclosed undisclosed litigation, or because key customer contracts contain change-of-control provisions that trigger price adjustments or termination rights; early identification of these issues allows negotiating parties to address them before signing and closing.

Regulatory compliance review examines whether the target company holds all required licenses, permits, and approvals and whether the transaction itself requires regulatory filings or approvals. This includes antitrust review under federal and state law, industry-specific approvals (such as those required for healthcare transactions like hospital mergers and acquisitions), environmental permits, and data privacy compliance. Failure to identify regulatory hurdles early can delay closing by months or create post-closing liability if the target company was operating without required approvals.

Standard representations typically address title to assets, compliance with laws, financial statements accuracy, absence of undisclosed liabilities, employee matters, intellectual property ownership, and absence of material adverse changes. Each representation should be specific to the target company and the industry; generic language often leads to disputes about scope and materiality. Negotiating the basket (threshold for indemnification claims), cap (maximum indemnification exposure), and survival period (how long representations remain in effect) requires balancing buyer protection against seller risk aversion.

Representation and warranty insurance transfers certain indemnification risk to an insurance carrier, reducing the need for seller holdback funds or post-closing disputes. This approach has become increasingly common in mid-market and larger transactions because it provides the buyer with a claim mechanism that does not depend on seller solvency or cooperation. From a practitioner's perspective, the decision to use insurance depends on deal size, seller creditworthiness, and the buyer's risk tolerance; smaller deals or those with strong seller backing may not justify the insurance premium.

New York courts apply a framework requiring that closing conditions be satisfied or waived before a party can refuse to close. If a buyer attempts to terminate based on a closing condition that has not been satisfied, the seller can seek specific performance or damages. The court will examine whether the condition was satisfied, whether it was waived, or whether the buyer's own conduct prevented satisfaction. In a transaction involving a New York target company or New York-based buyer, this means that vague or subjective closing conditions (such as no material adverse change) will be interpreted narrowly against the party trying to invoke them, and the burden of proof rests on the party claiming the condition was not satisfied.

Closing mechanics include purchase price adjustments for working capital changes, escrow arrangements for indemnification claims, and the mechanics of transferring assets and assuming liabilities. A detailed closing checklist and clear allocation of closing obligations reduce delays and disputes. Many transactions use an earn-out structure, where part of the purchase price is contingent on the target company meeting specified performance metrics after closing; these arrangements are common but frequently generate disputes about calculation methodology and the buyer's obligation to operate the business in a manner that allows earn-out targets to be met.